Pezadeftide

Hexima is conducting a phase IIb clinical trial of its lead antifungal molecule, pezadeftide (previously HXP124), as a potential topical treatment for fungal nail infections (onychomycosis). 

Investor Webinar 29 July 2021

Latest NailMail Newsletter

Hexima is holding an Investor Webinar on 29 July 2021 at 9am (AEST) to provide an insight into our presentation at the upcoming APMA conference and an update on the company’s activities.

NailMail is Hexima’s regular quarterly newsletter to shareholders, investors and interested parties.

Investor Webinar 29 July 2021

Hexima is holding an Investor Webinar on 29 July 2021 at 9am (AEST) to provide an insight into our presentation at the upcoming APMA conference and an update on the company’s activities.

Latest NailMail Newsletter

NailMail is Hexima’s regular quarterly newsletter to shareholders, investors and interested parties.

External Links

Take a look at these useful links to learn more about our industry.

Australian Academy of Science
Australian Science Media Centre logo